home / stock / phas / phas quote
Last: | $0.0701 |
---|---|
Change Percent: | 15.05% |
Open: | $0.0807 |
Close: | $0.0701 |
High: | $0.092 |
Low: | $0.0665 |
Volume: | 8,640,505 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.0701 | $0.0807 | $0.0701 | $0.092 | $0.0665 | 8,640,505 | 11-02-2022 |
$0.095 | $0.125 | $0.095 | $0.125 | $0.0768 | 27,002,948 | 11-01-2022 |
$0.1034 | $0.1112 | $0.1034 | $0.126 | $0.099 | 4,902,182 | 10-31-2022 |
$0.107 | $0.1398 | $0.107 | $0.1398 | $0.101 | 3,652,517 | 10-28-2022 |
$0.1318 | $0.1215 | $0.1318 | $0.144 | $0.1211 | 3,225,450 | 10-27-2022 |
$0.1217 | $0.1271 | $0.1217 | $0.1348 | $0.1211 | 4,451,417 | 10-26-2022 |
$0.135 | $0.1549 | $0.135 | $0.1549 | $0.13 | 9,877,958 | 10-25-2022 |
$0.1409 | $0.1805 | $0.1409 | $0.2091 | $0.12 | 7,517,527 | 10-24-2022 |
$0.1981 | $0.199 | $0.1981 | $0.2 | $0.1878 | 348,377 | 10-21-2022 |
$0.1976 | $0.191 | $0.1976 | $0.2024 | $0.1899 | 283,414 | 10-20-2022 |
$0.1904 | $0.21 | $0.1904 | $0.21 | $0.188 | 295,463 | 10-19-2022 |
$0.195 | $0.2005 | $0.195 | $0.2058 | $0.1856 | 574,933 | 10-18-2022 |
$0.197 | $0.214 | $0.197 | $0.214 | $0.1906 | 424,119 | 10-17-2022 |
$0.2076 | $0.201 | $0.2076 | $0.225 | $0.1938 | 783,653 | 10-14-2022 |
$0.201 | $0.1884 | $0.201 | $0.204 | $0.181 | 1,440,150 | 10-13-2022 |
$0.1905 | $0.1811 | $0.1905 | $0.195 | $0.18 | 947,423 | 10-12-2022 |
$0.1811 | $0.189 | $0.1811 | $0.19 | $0.18 | 470,748 | 10-11-2022 |
$0.1817 | $0.2 | $0.1817 | $0.2 | $0.1811 | 1,358,601 | 10-10-2022 |
$0.1819 | $0.195 | $0.1819 | $0.195 | $0.18 | 539,581 | 10-07-2022 |
$0.1933 | $0.18 | $0.1933 | $0.2 | $0.177 | 846,298 | 10-06-2022 |
News, Short Squeeze, Breakout and More Instantly...
PhaseBio Pharmaceuticals Inc. Company Name:
PHAS Stock Symbol:
NASDAQ Market:
Bidding Process and Auction Projected to Conclude December 2022 PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today announced that...
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today reported financial results for the second quarter ended June 30, 2022, and provided an upd...